✦ LIBER ✦

LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre

✍ Scribed by Perz, J B; Giles, C; Szydlo, R; O'Shea, D; Sanz, J; Chaidos, A; Wagner, S; Davis, J; Loaiza, S; Marin, D

Book ID: 110015171
Publisher: Nature Publishing Group
Year: 2006
Tongue: English
Weight: 149 KB
Volume: 39
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bmt.1705544

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

LACE-conditioned autologous stem cell tr

LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre

✍ Jiří Pavlů; Holger W. Auner; Sarah Ellis; Richard M. Szydlo; Chrissy Giles; Alej 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a recognized treatment option for patients with relapsed diffuse large B-cell lymphoma. We have analysed 51 patients who underwent ASCT after LACE (lomustine (CCNU), cytarabine (Ara-C), cyclophosphamide, etoposide) con

Allogeneic or autologous stem cell trans

Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience

✍ D. Nachbaur; W. Oberaigner; E. Fritsch; W. Nussbaumer; G. Gast 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

Early relapse and refractory disease rem

Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis

✍ Paul Greaves; Andrew Wilson; Janet Matthews; Daniel L. P. Brown; Rebecca Auer; S 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

Cost analysis and quality of life assess

Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial

✍ M van Agthoven; E Vellenga; W.E Fibbe; T Kingma; C.A Uyl-de Groot 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 159 KB

Gemcitabine, Busulfan and Melphalan (Gem

Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT)

✍ Y. Nieto; R.B. Jones; U. Popat; B. Andersson; B. Valdez; P. Thall; E.J. Shpall; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

High dose therapy and autologous stem ce

High dose therapy and autologous stem cell transplant does not improve survival compared with continued combination chemotherapy in people at high risk of relapse after initial treatment of advanced Hodgkin’s lymphoma: Abstracted from: Federico M, Bellei M, Brice P et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. Journal of Clinical Oncology 2003; 21: 2320–2325

📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 83 KB